ly2189102
mAbexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2005 (NCT00380744)
Timeline
Indications
Mechanism of action
- Interleukin-1 betaINHIBITOR
IL1B inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- ly2189102
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00942188 | Phase 2 | Jun 1, 2009 | Eli Lilly |
| NCT00380744 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2005 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 1 | 2005 |
1 organizations
Page 1 / 1